No profile data available.
IGC Pharma, Inc. (IGC) is an essential consumer products company in the marijuana product manufacturing industry, based in Potomac, United States, with about 70 full-time employees.
It reported revenue of $1.27 million for fiscal year 2025, down 5.5% from fiscal year 2024, and net income of -$7.12 million. United States of America was its largest region in fiscal year 2025, with 100% of revenue. Its market capitalization was $28.94 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
, a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
IGC Pharma reported $1.27 million in revenue for fiscal year 2025, down 5.5% from $1.35 million in fiscal year 2024.
United States of America: 100% of revenue by region in fiscal year 2025, followed by Colombia (under 1%).
$28.94 million as of October 9, 2026.
Listed companies of a similar size in the same industry (marijuana product manufacturing) include InterCure Ltd. (INCR), Healthier Choices Management Corp. (HCMC), Leef Brands Inc. (LEEEF), MariMed Inc. (MRMD).